1. 1. Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y, Ma J (2019) Nasopharyngeal carcinoma. Lancet, (London, England), 394(10192): 64-80. [DOI:10.1016/S0140-6736(19)30956-0]

2. Chang ET, Ye W, Zeng YX, Adami HO (2021) The evolving epidemiology of nasopharyngeal carcinoma. Cancer epidemiology, biomarkers & prevention: A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 30(6): 1035-1047. [DOI:10.1158/1055-9965.EPI-20-1702]

3. Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, Sampath S, Amini A, et al. (2023) Recurrent/metastatic nasopharyngeal carcinoma treatment from present to future: Where are we and where are we heading? Current Treatment Options in Oncology, 24(9): 1138-1166. [DOI:10.1007/s11864-023-01101-3]

4. Su ZY, Siak PY, Lwin YY, Cheah SC (2024) Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Reviews, 43(3): 919-939. [DOI:10.1007/s10555-024-10176-9]

5. Bossi P, Chan AT, Licitra L, Trama A, Orlandi E, Hui EP, Halámková J, Mattheis S, Baujat B, Hardillo J, Smeele L, van Herpen C, Castro A, Machiels JP, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, & EURACAN (2021) Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 32(4): 452-465. [DOI:10.1016/j.annonc.2020.12.007]

6. Yan C, Wang R, Zhang C, Lin G, Du Y, Chen M, et al. (2025) Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF. Oral Oncology, 160: 107119. [DOI:10.1016/j.oraloncology.2024.107119]

7. Hua X, Li WZ, Huang X, Wen W, Huang HY, Long ZQ, et al. (2021) Modeling sarcopenia to predict survival for patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy. Frontiers in Oncology, 11: 625534. [DOI:10.3389/fonc.2021.625534]

8. Qian S, Zhang S, Lu M, Chen S, Liu L, Liu S, et al. (2024) The accuracy of screening tools for sarcopenia in older Chinese adults: a systematic review and meta-analysis. Frontiers in Public Health, 12: 1310383. [DOI:10.3389/fpubh.2024.1310383]

9. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2 (2019) Sarcopenia: Revised European consensus on definition and diagnosis. Age and Ageing, 48(1): 16-31. [DOI:10.1093/ageing/afy169]

10. Meza-Valderrama D, Marco E, Dávalos-Yerovi V, Muns MD, Tejero-Sánchez M, Duarte E, Sánchez-Rodríguez D (2021) Sarcopenia, malnutrition, and cachexia: adapting definitions and terminology of nutritional disorders in older people with cancer. Nutrients, 13(3): 761. [DOI:10.3390/nu13030761]

11. Lee B, Bae YJ, Jeong WJ, Kim H, Choi BS, Kim JH (2021) Temporalis muscle thickness as an indicator of sarcopenia predicts progression-free survival in head and neck squamous cell carcinoma. Scientific Reports, 11(1): 19717. [DOI:10.1038/s41598-021-99201-3]

12. Mukai T, Kobayashi K, Yamamura K, Fukuoka O, Kondo K, Saito Y (2024) Prognostic value of pretreatment temporal muscle thickness after curative surgery for oral cavity squamous cell carcinoma. Int J Clinical Oncology, 29(10): 1444-1450. [DOI:10.1007/s10147-024-02591-3]

13. Tang J, Dong Z, Yang L, Yang P, Zhao W, Deng L, et al. (2024) The relationship between prognosis and temporal muscle thickness in 102 patients with glioblastoma. Scientific Reports, 14(1): 13958. [DOI:10.1038/s41598-024-64947-z]

14. McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS (2001) Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutrition and Cancer, 39(2): 210-213. [DOI:10.1207/S15327914nc392_8]

15. Xu H, Zheng X, Ai J, Yang L (2023) Hemoglobin, albumin, lymphocyte, and platelet (HALP) score and cancer prognosis: A systematic review and meta-analysis of 13,110 patients. International Immunopharmacology, 114: 109496. [DOI:10.1016/j.intimp.2022.109496]

16. Kang D, Liu S, Yuan X, Liu S, Zhang Z, He Z, et al. (2023) A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors. Journal of Cancer Research and Clinical Oncology, 149(20):18215-18240. [DOI:10.1007/s00432-023-05504-5]

17. Yiu CY, Liu CC, Wu JY, Tsai WW, Liu PH, Cheng WJ, et al. (2023) Efficacy of the geriatric nutritional risk index for predicting overall survival in patients with head and neck cancer: A meta-analysis. Nutrients, 15(20): 4348. [DOI:10.3390/nu15204348]

18. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumor Marker prognostic studies (REMARK). British Journal of Cancer, 93(4): 387-391. [DOI:10.1038/sj.bjc.6602678]

19. Li WF, Sun Y, Chen M, Tang LL, Liu LZ, Mao YP, et al. (2012) Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation. Chinese Journal of Cancer, 31(12): 579-587. [DOI:10.5732/cjc.012.10095]

20. Lee AW, Ng WT, Pan, JJ et al. (2018) International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 126(1): 25-36. [DOI:10.1016/j.radonc.2017.10.032]

21. Chen YP, Ismaila N, Chua MLK, et al. (2021) Chemotherapy in combination with radiotherapy for definitive-intent treatment of stage II-IVA nasopharyngeal carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology, 39(7): 840-859. [DOI:10.1200/JCO.20.03237]

22. Ten Cate C, Huijs SMH, Willemsen ACH, et al. (2022) Correlation of reduced temporal muscle thickness and systemic muscle loss in newly diagnosed glioblastoma patients. Journal of Neuro-Oncology, 160(3): 611-618. [DOI:10.1007/s11060-022-04180-8]

23. Unal I (2017) Defining an Optimal Cut-Point Value in ROC Analysis: An Alternative Approach. Computational and Mathematical Methods in Medicine, 2017: 3762651. [DOI:10.1155/2017/3762651]

24. Huang H, Yao Y, Deng X, et al. (2023) Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review). International Journal of Oncology, 63(2): 97. [DOI:10.3892/ijo.2023.5545]

25. Jovanovic N, Chinnery T, Mattonen SA, Palma DA, Doyle PC, Theurer JA (2022) Sarcopenia in head and neck cancer: A scoping review. PloS one, 17(11), e0278135. [DOI:10.1371/journal.pone.0278135]

26. Kamada T, Ohdaira H, Ito E et al (2022) Association between masseter muscle sarcopenia and postoperative pneumonia in patients with esophageal cancer. Scientific Reports, 12(1): 16374. [DOI:10.1038/s41598-022-20967-1]

27. Huang X, Lv LN, Zhao Y, Li L, Zhu XD (2021) Is skeletal muscle loss associated with chemoradiotherapy toxicity in nasopharyngeal carcinoma patients? A prospective study. Clinical Nutrition (Edinburgh, Scotland), 40(1): 295-302. [DOI:10.1016/j.clnu.2020.05.020]

28. Liu S, Zou Y, Zhong M, Li T, Cao Y, Wang R, et al. (2023) Prognostic significance of MRI-defined sarcopenia in patients with nasopharyngeal carcinoma: A propensity score matched analysis of real-world data. Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology, 188: 109904. [DOI:10.1016/j.radonc.2023.109904]

29. He WZ, Jiang C, Liu LL, et al. (2020) Association of body composition with survival and inflammatory responses in patients with non-metastatic nasopharyngeal cancer. Oral Oncology, 108: 104771. [DOI:10.1016/j.oraloncology.2020.104771]

30. Sadhwani N, Aggarwal A, Mishra A, Garg K (2022) Temporal muscle thickness as an independent prognostic marker in glioblastoma patients-a systematic review and meta-analysis. Neurosurgical Review, 45(6): 3619-3628. [DOI:10.1007/s10143-022-01892-3]

31. Muglia R, Simonelli M, Pessina F, et al. (2021) Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis. European Radiology, 31(6): 4079-4086. [DOI:10.1007/s00330-020-07471-8]

32. Klingenschmid J, Krigers A, Pinggera D, et al. (2024) Temporal Muscle Thickness Compared to Functional Scales as a Prognostic Parameter in Patients with Brain Metastases. Cancers, 16(9): 1660. [DOI:10.3390/cancers16091660]

33. Kim YI, Shin JY, Yang SH, Kim HH, Shim BY, Ahn S (2022) Association between temporal muscle thickness and overall survival in non-small cell lung cancer patients with brain metastasis. Current Oncology (Toronto, Ont.), 29(9): 6463-6471. [DOI:10.3390/curroncol29090508]

34. He Y, Chen X, Yang T, Li Y, Tan S, Liu X (2023) Nutritional intervention for the prognosis of nasopharyngeal carcinoma chemoradiotherapy patients: A meta-analysis. Medicine, 102(41): e35386. [DOI:10.1097/MD.0000000000035386]

35. Li G, Gao J, Liu ZG, et al. (2014) Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution. Head & Neck, 36(5): 660-666. [DOI:10.1002/hed.23357]

36. Yang H, Wang K, Liang Z, Guo S, Zhang P, Xu Y, Zhou H (2020) Prognostic role of pre-treatment serum albumin in patients with nasopharyngeal carcinoma: A meta-analysis and systematic review. Clinical otolaryngology: official journal of ENT-UK; Official Journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 45(2): 167-176. [DOI:10.1111/coa.13454]

37. Koca T, Cetmi DA, Aksoy RA, Korcum AF (2024) The predictive role of inflammatory biomarkers in patients with larynx cancer undergoing definitive radiotherapy. Technology in Cancer Research & Treatment, 23: 15330338241280433. [DOI:10.1177/15330338241280433]

38. Zhang N, Hou T, Zhang S, et al. (2024) Prognostic significance of pan-immune-inflammation value (PIV) in nasopharyngeal carcinoma patients. Heliyon, 10(2): e24804. [DOI:10.1016/j.heliyon.2024.e24804]

39. Topkan E, Selek U, Ozturk D, Şenyürek Ş, Kılıç Durankuş N (2024) Prognostic value of pre-chemoradiotherapy pan-immune-inflammation value (PIV) in locally advanced nasopharyngeal cancers. Cancer control: Journal of the Moffitt Cancer Center, 31: 10732748241290746. [DOI:10.1177/10732748241290746]

40. Kim JH, Mualla R, Mace JC et al (2023) Effect of sarcopenia on survival outcomes in patients with nasopharyngeal and sinonasal cancer. International forum of allergy & rhinology, 13(8), 1554-1557. https://doi.org/10.1002/alr.23112 [DOI:10.1002/alr.23112.]

41. Hua X, Liao JF, Huang X et al (2020) Sarcopenia is associated with higher toxicity and poor prognosis of nasopharyngeal carcinoma. Therapeutic advances in medical oncology, 12, 1758835920947612. https://doi.org/10.1177/1758835920947612 [DOI:10.1177/1758835920947612.]

42. Liu T, Wang G, Chen C, He L, Wang R (2024) Prognostic value of sarcopenia in the patients with locally advanced nasopharyngeal carcinoma. Japanese journal of radiology, 42(9), 1047-1057. https://doi.org/10.1007/s11604-024-01587-3 [DOI:10.1007/s11604-024-01587-3.]

43. Huang X, Ma J, Li L, Zhu XD (2019) Severe muscle loss during radical chemoradiotherapy for non-metastatic nasopharyngeal carcinoma predicts poor survival. Cancer medicine, 8(15), 6604-6613. https://doi.org/10.1002/cam4.2538 [DOI:10.1002/cam4.2538.]

44. Huang HY, Lin F, Chen XY et al (2021) A Model Combining Skeletal Muscle Mass and a Hematological Biomarker to Predict Survival in Patients With Nasopharyngeal Carcinoma Undergoing Concurrent Chemoradiotherapy. Frontiers in oncology, 11, 644676. https://doi.org/10.3389/fonc.2021.644676 [DOI:10.3389/fonc.2021.644676.]